Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1998

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Preliminary studies with recombinant chorionic gonadotropin beta-subunit

produced in Escherichia coli for use as an antigen in a birth control

vaccine.

AUTHORS

Mukhopadhyay A; Bhatia PK; Majumdar SS

SOURCE

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY. 1998 Mar;39(3):172-82.

ABSTRACT

An early signal for conception, human chorionic gonadotropin (hCG) is considered essential for the establishment

and maintenance of early pregnancy by stimulating the corpus luteum and continuing the secretion of progesterone

until the placenta takes over the function. The active immunization of women against hCG has therefore been

considered to be a promising option for contraception. Prototype human chorionic gonadotropin (hCG) vaccines

based upon natural sources, however, are unsuitable for widespread applications due to their complex manufacturing

procedures, cost, and carrier-mediated immune suppression. The authors report the use of CGB produced in E. coli

as a potential antigen for use in a birth control vaccine. The nonglycosylated recombinant CGB either alone or upon

conjugation to TT was used for immunization to evaluate its immunogenic potency as a birth control vaccine, and to

compare it with urinary CGB vaccine (nCGB-TT). Wistar rats were immunized with alum-adsorbed CGB, CGB-TT,

and nCGB-TT, while Bonnet monkeys were immunized with only CGB. The anti-hCG antibody titre in the sera

obtained at different time points were quantified by radioimmunoassay. The sera of Wistar rats were characterized

with regard to their affinity to hCG, bioneutralization capacity, and cross-reactivity with human luteinizing hormone,

human follicle-stimulating hormone, and human thyroid-stimulating hormone. The antigen-binding capacities of sera

obtained upon immunization with CGB were 3080 +or- 943 ng/ml (n = 6) and 3993 +or- 1292 ng/ml (n = 4),

respectively, in rats and monkeys. Data analysis showed that immunization of rats with CGB produced antibodies

comparable to that of CGB-TT and nCGB-TT. (PubHealth.info Document ID: CONT2T 50-06)

PubHealth.info NOTE: The author(s) of this article titled, "Preliminary studies with recombinant chorionic

gonadotropin beta-subunit produced in Escherichia coli for use as an antigen in a birth control vaccine.", is(are)

Mukhopadhyay A; Bhatia PK; Majumdar SS. The source of this article is "AMERICAN JOURNAL OF

REPRODUCTIVE IMMUNOLOGY. 1998 Mar;39(3):172-82.". This article was published in 1998 in English

language(s). (PubHealth.info® Document ID: CONT2T 50-06. All rights reserved with PubHealth.info) PIN: 5050

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.